We are live on ! Find out more
RGN

REGENERX BIOPHARMACEUTICALS
RGN

Delisted

RGN was delisted on the 22nd of December, 2010.

Back to rankings

1 hedge funds and large institutions have $170 invested in REGENERX BIOPHARMACEUTICALS in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

36% less capital invested

Capital invested by funds: $266 → $170 (-$96)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WJWM
1
Williams Jones Wealth Management
New York
$170 – – –

RGN Hedge Fund Activity: Q3 2023 in Review

1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2023, worth a combined $170 — down 36% from $266 a quarter earlier.

Fund positioning in RGN was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $170 of REGENERX BIOPHARMACEUTICALS stock for Q3 2023, down 36% quarter-over-quarter.
  • 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2023 and 0 closed out.

Based on aggregated 13F filings for Q3 2023.